FIELD: biochemistry.
SUBSTANCE: invention relates to an isolated antibody to a coagulation factor that specifically binds to human FXI. A pharmaceutical composition for inhibiting the formation of blood clots using the said antibody is also disclosed. The uses of the said antibody to inhibit the formation of blood clots in a subject, in the manufacture of a medicinal product for the treatment or inhibition of the onset of sepsis; a method of inhibiting the formation of blood clots in a subject; a method of treating or inhibiting the occurrence of thrombosis or a complication or condition, a method of treating or inhibiting the occurrence of sepsis; a method of obtaining the said antibody are disclosed.
EFFECT: invention makes it possible to effectively treat conditions associated with coagulation.
18 cl, 13 dwg, 3 tbl, 11 ex
| Title | Year | Author | Number |
|---|---|---|---|
| BISPECIFIC ANTIBODIES | 2020 |
|
RU2818588C2 |
| MONOCLONAL BINDING AGENTS, THEIR DRUG CONJUGATES AND THEIR APPLICATIONS | 2017 |
|
RU2744914C2 |
| PARTICLES CONJUGATED TO PEPTIDE | 2014 |
|
RU2813163C2 |
| AIMED AT UPARAP ANTIBODY-DRUG CONJUGATES | 2017 |
|
RU2740311C2 |
| DRUG CONJUGATES FROM MONOCLONAL CMET BINDING AGENTS AND THEIR USE | 2019 |
|
RU2813828C2 |
| ANTI-PCSK9 ANTIBODY AND ITS APPLICATION | 2016 |
|
RU2756012C2 |
| MONOCLONAL ANTIBODIES TO INTERLEUKIN-31 FOR VETERINARY USE | 2019 |
|
RU2795411C2 |
| ANTIBODY AGAINST HUMAN INTERLEUKIN-4 ALPHA RECEPTOR, METHOD OF ITS PREPARATION AND ITS APPLICATION | 2021 |
|
RU2807060C1 |
| PHARMACEUTICAL COMPOSITION FOR TREATMENT AND/OR PREVENTION OF MALIGNANT TUMOR | 2019 |
|
RU2781542C2 |
| THERAPEUTIC ANTI-CANCER NEOEPITOPE VACCINE | 2017 |
|
RU2782422C2 |
